Result: Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

*Title*:

*Author/editor-in-chief*:

*Publication*:

Freiburg : Universität, 2019

*Physical description scale*:

Online-Ressource

*Format*:

*eBook*

*Language*:

*eng*

*Subject Added Keywords*:

*DOI*:

10.1186/s12885-018-5045-7

*Result*: Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)